Based on the observations that chemerin levels are increased in patients with autoimmune diseases, such as rheumatoid arthritis, this laboratory aims at defining the role of chemerin and its receptors, in preclinical models of inflammatory arthritis, with the aim to define the role of these proteins in the pathogenesis and severity of this disease and the final goal to define the possible use of CCRL2 as a new therapeutic target and biological marker of successful therapy.